JP Morgan Upgrades Pacira BioSciences to Neutral from Underweight
Fintel reports that on October 8, 2026, JP Morgan upgraded their outlook for Pacira BioSciences (NASDAQGS:PCRX) (DB:82P) from Underweight to Neutral.
Pacira BioSciences, Inc., based in the United States, operates within the pharmaceutical industry and is primarily focused on the development, manufacture, and commercialization of non-opioid pain management and regenerative health solutions. A key product in their portfolio is EXPAREL, a liposome injection of bupivacaine, an anesthetic, designed to provide long-lasting pain relief without the use of opioids following surgery.
On October 8, 2026, the latest close for the stock was $36.40, which compares to a pre-action close of $25.20 on October 7, 2026. The stock experienced a price change of +45.54% over one week, relative to a baseline close of $25.01 on October 1, 2026. Over a one-month period, the price change was +40.70% from a baseline close of $25.87 on September 8, 2026.
As of October 2, 2026, the current consensus target mean for the stock was $29.84, with a median target of $29.58. This mean target represents an implied change of -18.04% from the stock's valuation. The prior consensus target mean was $29.43 as of September 15, 2026, representing a consensus target revision of +1.36%.
For the current recommendation period of September 1, 2026, the aggregate analyst recommendations consisted of 3 strong buy, 6 buy, 3 hold, and 1 sell ratings, totaling 13 recommendations. This breakdown represents 69.2% positive, 23.1% hold, and 7.7% negative recommendations. In the prior period of August 1, 2026, there were 12 total recommendations, consisting of 3 strong buy, 5 buy, 3 hold, and 1 sell ratings, which represented 66.7% positive, 25.0% hold, and 8.3% negative recommendations.
Other recent analyst actions include Truist Securities maintaining a Buy rating on October 7, 2026. Prior to that, Oppenheimer initiated coverage with an Outperform rating on September 23, 2026, and Leerink Partners initiated coverage with a Market Perform rating on September 9, 2026.
In its latest earnings report on August 4, 2026, Pacira BioSciences reported an actual EPS of 0.73, compared to an estimate of 0.6603, representing an EPS surprise of +10.56%. The actual revenue for the quarter was $192,399,000.00, compared to an estimated revenue of $194,632,728.00. The company's upcoming earnings date is scheduled for November 4, 2026.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 8, 2026 | JP Morgan | Underweight | Neutral | upgrade |
| October 7, 2026 | Truist Securities | Buy | Buy | maintained |
| September 23, 2026 | Oppenheimer | Outperform | initiated coverage | |
| September 9, 2026 | Leerink Partners | Market Perform | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.